The NRCANCER project has as its main objective the DEVELOPMENT OF A NEW Antitumor Therapy based on the described effect of riboside NICOTINAMIDA (-NR-a form of vitamin B3) aimed at raising endogenous levels of coenzyme NAD+, which prevent the effects of genotoxic damage caused by its deficiency and therefore halt tumor growth. NRCANCER is aimed at the clinical efficacy test in humans of vitamin B3 precursor Nicotinamida-Ribóside on hepatocellular carcinoma and pancreatic carcinoma, both tumors with low therapeutic efficacy. This project is based on the incipient field of the application of advances in the knowledge of the metabolism of the cancer cell in new therapeutic approaches, being the final objective proposed is the VALIDATION AND STEP IN MARKET OF An antitumor TERAPY based on the administration of Nicotinamide Ribósido, whose effect on liver carcinoma has already been demonstrated in animal models in vivo. To address the project, the NRCANCER consortium has been established designed to join efforts thanks to the collaboration of biotechnology companies and R & D centers with complementary specialties. In this consortium are: (1) STEMTEK THERAPEUTICS: with experience in the research of new therapeutics in Oncology; (2) Tecnalia: with experience in the design and management of clinical trials in humans in the area of Oncology; and (3) National Center for Oncological Research, CNIO-: international reference pointer center in oncological research. The Project is structured globally in FOUR HITES that are integrated together over the three years of the same. The facts that make up the development of the Project are: MILESTONE-1. Synthesis AND OBTENTION OF NR IN CONDITIONS cGMP (2016-2017) HITO-2. PRECLINICAL EVALUATION OF THE ANTI-TUMOR EFFECT OF NR IN PANCREATIC CARCINOMA (2016-18) MILESTONE-3. Evaluation OF ANTI-TUMORAL ACTIVITY OF NR IN HUMANS (2017-19) HITO-4.DESIGN OF COMMERCIAL AND COMMERCIALISATION STRATEGY (2016-19) The market subject of the project is one that demands new technologies or effective solutions for the treatment of liver cancer and other tumors with low therapeutic efficacy, such as pancreatic carcinoma. The pharmaceutical industry is the main applicant for new anti-tumor therapies for oncological treatments. The NRCANCER consortium has the European patent application (CNIO) on the use in Oncology of NR, proposes to develop a new patent with the inventive property resulting from the project: Method of obtaining NR by chemical synthesis. The development of these patents will be carried out in the consortium. Within the consortium, the necessary regulatory clinical tests will be carried out to evaluate the therapeutic effect of NR, following the guidelines of the Spanish Agency for Medicines and Medical Devices (AEMPS). The marketing strategy will seek the licensing of the technology to a third party with implantation in specific markets or direct marketing through a dedicated legal instrument (spin-off of the consortium), once the human efficacy test has been carried out, with a favorable result, when it is precisely possible to obtain the jump in valuation and great economic returns in the development of therapeutics.